
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a strong portfolio of clinical-stage assets targeting depressive disorders and schizophrenia populations. Their approach to redefine psychiatry through personalized and effective treatment options shows potential for success. Although a delay in the readout timing of ALTO-100 and ALTO-300 may cause disappointment, it does not significantly impact the company's valuation. With a quarterly burn of ~$22M, the company is on track to achieve its cash runway guidance through 2029. Alto's focus on biomarker analysis and commercial differentiation strategies could position them for success in a competitive market. However, there are risks to achieving target prices, including clinical and regulatory challenges and the unproven nature of their biomarker approach.
Bears say
Alto Neuroscience is a clinical-stage biopharmaceutical company with a high degree of clinical and regulatory risk. Their precision psychiatry platform has potential, but it has yet to be proven and their drug candidates such as ALTO-100 and ALTO-101 have had limited success in clinical trials. The company will also face financial and commercial risks as they continue to develop and commercialize their therapies. Their current valuation is based on forward assumptions and third-party reliance, making it uncertain and potentially overvalued in the long-term.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares